论文部分内容阅读
人鼻病毒(human rhinovirus,HRV)是引起病毒性呼吸道感染的最常见病原体,目前尚无有效治疗药物。由于HRVs绝大多数血清型仅对灵长类动物易感,对常用实验动物不感染,目前多在细胞水平对抗HRVs药物进行筛选与评价,这对抗HRVs药物的有效性研究明显不足。本文根据HRVs对呼吸道感染的特点,以离体气管平滑肌(ASM)收缩反应变化为评价指标,建立了可模拟呼吸症状的筛选模型,在此模型上接种鼻病毒后ASM对于激动剂引发的收缩反应显著增强150%,舒张反应明显减弱至63%,而预先加入已经过细胞初筛有效的化合物后,可显著改善鼻病毒引发的收缩反应异常,表明所建立的评价模型可用于抗鼻病毒药物的进一步筛选。
Human rhinovirus (HRV) is the most common causative agent of viral respiratory tract infections and there is no effective treatment for it. Because most serotypes of HRVs are only susceptible to primates, they are not infected with commonly used experimental animals. At present, most of the HRVs serotypes are screened and evaluated against HRVs at the cellular level, and the study on the effectiveness of anti-HRVs drugs is obviously insufficient. According to the characteristics of respiratory tract infection of HRVs and the changes of isolated tracheal smooth muscle (ASM) contraction as the evaluation index, a screening model that can simulate respiratory symptoms was established. After the rhinovirus was inoculated, the ASM response to agonist-induced contractions Significantly increased 150%, diastolic response was significantly weakened to 63%, and pre-added cells have been effective after screening compounds can significantly improve rhinovirus-induced contractile response abnormalities, indicating that the established evaluation model can be used for anti-rhinovirus drugs Further screening.